About the Company

Activities Of The Company

Biocontrol has now developed a novel system for controlling bacterial infection with Pseudomonas aeruginosa using biological agents. This has proven efficacy and safety even where conventional antibiotics have failed.

This product has now completed human Phase I/IIa clinical trials, and treatment of patients is now under way, with multiple treatments completed.

Biocontrol has:

Lead product now in clinical trials with strong commercial prospects
Access to world-class scientific expertise in established centres of excellence
A strong portfolio of intellectual property based around filed patent applications
Contracted collaborative links, substantially reducing the expenditure and time required for product development
An experienced and highly entrepreneurial business team
Outstanding business opportunities in large, expanding and poorly served markets

The development streams undertaken to date form the basis for Biocontrol Ltd. to establish itself as the market-leading company in the expanding field of bacteriophage-based therapeutics

Chemical agents have served well, but are failing. They are far more damaging than was at first realised, and resistance is a huge and increasing problem. In summary:

Life Adapts

Chemicals Do Not

A new approach is needed

Biocontrol is providing that approach

Management and Scientific Advisors

The Chairman of Biocontrol is Mrs. Caroline Williams. Mrs. Williams is a corporate lawyer, Chairman of Hampshire Economic Partnership, Chairman of Portsmouth Historic Dockyard, former Chairman of the University of Portsmouth, and a former director of SEEDA. In addition she is Chairman of BC Capital Ltd. the financial advisers to the Company.

Professor Erik Änggård is a director and is also the Chairman of the Scientific Advisory Board of the company. Professor Änggård was Director General of the William Harvey Research Institute, London. He was also a founder of Vanguard Medica, and held the post of Director of Research & Development at Bristol-Myers.

Mrs Tuula Moilanen is the Chief Financial Officer and Company Secretary. She has worked in international banking, senior finance management internationally and published widely on financial evaluation of technologies. In the past ten years, she has been involved in incubating a number of high-technology companies, particularly in biotechnology and medical technologies.

Mr. David Scott is the Commercial Director of the company, with special responsibilty for licensing. Mr Scott is the author of the best-selling report, "Scrip's Practical Guide to Pharmaceutical Licensing", and is a skilled negotiator with proven skills in deal making.

Mr. Nigel Evans is a non-executive director of the company, and acts as shareholder representative. Mr. Evans is an experienced commercial manager and is active elsewhere in the biotechnology sector as Chairman of Scancell Limited.

Dr. David Harper is the founder and Chief Scientific Officer of Biocontrol. Dr. Harper is an experienced project manager in commercial biomedical research. He is a virologist and medical author, and spent eight years on the faculty at St. Bartholomew's Hospital Medical College (Barts).

Dr. James Soothill developed the technologies on which the lead product of the company is based and is a member of the Scientific Advisory Board of the company.

Corporate Advisors

Biocontrol has a long-standing policy of using high quality corporate advisors.

The company is advised on financial matters by BC Capital, Southampton.

Intellectual property issues are handled by Marks & Clerk, Oxford.

Regulatory and clinical trials advice is provided by Parexel International, one of the largest pharmaceutical services companies in the world.

Other advisors provide input in specific areas such as licensing and human resources.